137 related articles for article (PubMed ID: 37792671)
21. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study.
Du Y; Sidorenkov G; Heuvelmans MA; Groen HJM; Vermeulen KM; Greuter MJW; de Bock GH
Eur J Cancer; 2020 Aug; 135():121-129. PubMed ID: 32563896
[TBL] [Abstract][Full Text] [Related]
22. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.
Treskova M; Aumann I; Golpon H; Vogel-Claussen J; Welte T; Kuhlmann A
BMC Med; 2017 Aug; 15(1):162. PubMed ID: 28838313
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
24. Economic impact of using risk models for eligibility selection to the International lung screening Trial.
Cressman S; Weber MF; Ngo PJ; Wade S; Behar Harpaz S; Caruana M; Tremblay A; Manser R; Stone E; Atkar-Khattra S; Karikios D; Ho C; Fernandes A; Yi Weng J; McWilliams A; Myers R; Mayo J; Yee J; Yuan R; Marshall HM; Fong KM; Lam S; Canfell K; Tammemägi MC
Lung Cancer; 2023 Feb; 176():38-45. PubMed ID: 36592498
[TBL] [Abstract][Full Text] [Related]
25. Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography.
Grover H; King W; Bhattarai N; Moloney E; Sharp L; Fuller L
Lung Cancer; 2022 Aug; 170():20-33. PubMed ID: 35700629
[TBL] [Abstract][Full Text] [Related]
26. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.
de Koning HJ; Meza R; Plevritis SK; ten Haaf K; Munshi VN; Jeon J; Erdogan SA; Kong CY; Han SS; van Rosmalen J; Choi SE; Pinsky PF; Berrington de Gonzalez A; Berg CD; Black WC; Tammemägi MC; Hazelton WD; Feuer EJ; McMahon PM
Ann Intern Med; 2014 Mar; 160(5):311-20. PubMed ID: 24379002
[TBL] [Abstract][Full Text] [Related]
27. A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.
Zhao Z; Gu S; Yang Y; Wu W; Du L; Wang G; Dong H
BMC Cancer; 2024 Jan; 24(1):73. PubMed ID: 38218803
[TBL] [Abstract][Full Text] [Related]
28. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of Lung Cancer Screening in Canada.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
JAMA Oncol; 2015 Sep; 1(6):807-13. PubMed ID: 26226181
[TBL] [Abstract][Full Text] [Related]
30. Risk prediction models versus simplified selection criteria to determine eligibility for lung cancer screening: an analysis of German federal-wide survey and incidence data.
Hüsing A; Kaaks R
Eur J Epidemiol; 2020 Oct; 35(10):899-912. PubMed ID: 32594286
[TBL] [Abstract][Full Text] [Related]
31. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis.
Wattson DA; Hunink MG; DiPiro PJ; Das P; Hodgson DC; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):344-53. PubMed ID: 25104066
[TBL] [Abstract][Full Text] [Related]
32. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.
Kumar V; Cohen JT; van Klaveren D; Soeteman DI; Wong JB; Neumann PJ; Kent DM
Ann Intern Med; 2018 Feb; 168(3):161-169. PubMed ID: 29297005
[TBL] [Abstract][Full Text] [Related]
33. Population-Based Screening Using Low-Dose Chest Computed Tomography: A Systematic Review of Health Economic Evaluations.
Behr CM; Oude Wolcherink MJ; IJzerman MJ; Vliegenthart R; Koffijberg H
Pharmacoeconomics; 2023 Apr; 41(4):395-411. PubMed ID: 36670332
[TBL] [Abstract][Full Text] [Related]
34. Cost Effectiveness of Lung Cancer Screening With Low-Dose CT in Heavy Smokers in China.
Yuan J; Sun Y; Wang K; Wang Z; Li D; Fan M; Bu X; Chen M; Ren H
Cancer Prev Res (Phila); 2022 Jan; 15(1):37-44. PubMed ID: 34580085
[TBL] [Abstract][Full Text] [Related]
35. Impact of low-dose CT screening for lung cancer on ethnic health inequities in New Zealand: a cost-effectiveness analysis.
McLeod M; Sandiford P; Kvizhinadze G; Bartholomew K; Crengle S
BMJ Open; 2020 Sep; 10(9):e037145. PubMed ID: 32973060
[TBL] [Abstract][Full Text] [Related]
36. Eligibility for low-dose computerized tomography screening among asbestos-exposed individuals.
Fitzgerald NR; Flanagan WM; Evans WK; Miller AB;
Scand J Work Environ Health; 2015 Jul; 41(4):407-12. PubMed ID: 25837734
[TBL] [Abstract][Full Text] [Related]
37. Lung cancer screening with low-dose computed tomography: National expenditures and cost-effectiveness.
Zeng X; Zhou Z; Luo X; Liu Q
Front Public Health; 2022; 10():977550. PubMed ID: 36249202
[TBL] [Abstract][Full Text] [Related]
38. Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.
Kregting LM; Sankatsing VDV; Heijnsdijk EAM; de Koning HJ; van Ravesteyn NT
Int J Cancer; 2022 Jul; 151(2):287-296. PubMed ID: 35285018
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of computed tomography screening for lung cancer in the United States.
McMahon PM; Kong CY; Bouzan C; Weinstein MC; Cipriano LE; Tramontano AC; Johnson BE; Weeks JC; Gazelle GS
J Thorac Oncol; 2011 Nov; 6(11):1841-8. PubMed ID: 21892105
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
